Immuron Plans Phase 2 Trial for IMM-529 following FDA review
Filed with ASX · · 3 pages · English
Earlier from Immuron
- Appendix 4E and Preliminary Final Report
- Immuron Travelan record sales globally, Australia and USA
- IMM-529 pre-IND FDA filing
- Immuron Travelan sales continued strong growth
- Travelan to progress to Phase 3 Clinical Trials in the US
Later from Immuron
- Trading Halt
- NMRC Reports Results for Campylobacter Clinical Study
- Immuron Announces Travelan Clinical Trial Update
- Immuron Travelan continued strong sales growth
- IMC and Calmino to treat Irritable Bowel Syndrome (IBS)
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron